Chosen from across the UK as one of just 10 high-potential MedTech ventures, we’re joining a prestigious 4-month programme designed to sharpen our go-to-market strategy, de-risk adoption, and scale VIOSync.
We’re proud to announce that Aisthesis Medical has been selected for the Innovate UK Biomedical Catalyst Accelerator: MedTech Venture Kickstarter — delivered by the London Institute for Healthcare Engineering (LIHE) in partnership with the Health Innovation Network South London.
Chosen from a competitive pool of applicants spanning the UK, we’re one of just 10 high-potential MedTech ventures to join this intensive, government-funded programme. It’s a strong external signal that VIOSync is ready for the next chapter.
About the MedTech Venture Kickstarter Programme
The MedTech Venture Kickstarter is an intensive 4-month accelerator programme funded by Innovate UK Biomedical Catalyst — one of the UK government’s primary mechanisms for supporting innovative life sciences and health technology companies.
It’s delivered by the London Institute for Healthcare Engineering at King’s College London — a world-class research and innovation hub working at the intersection of engineering and clinical medicine — in collaboration with the Health Innovation Network South London, which connects NHS organisations with innovative health technology.
The programme is explicitly designed to do what most accelerators don’t: tackle the specific commercial and adoption challenges that MedTech companies face when trying to move from promising technology to real-world NHS and hospital deployment.
What We’ll Be Working On Over the Next 4 Months
Working alongside LIHE’s expert team and the wider cohort, our focus will be on three interconnected goals for VIOSync:
- Sharpen go-to-market strategy: Refining how we position and commercialise VIOSync within NHS and private hospital environments, ensuring our value proposition is as clear for procurement teams as it is for clinicians.
- De-risk clinical adoption: Identifying and systematically addressing the barriers that slow down hospital AI adoption — from integration complexity and clinical workflow fit to evidence requirements and change management.
- Scale commercial readiness: Building the infrastructure, partnerships, and processes that allow VIOSync to move beyond individual pilots and into multi-site, scalable deployment across hospital networks.
Why This Matters for VIOSync — and for Patients
VIOSync helps clinical teams see sepsis risk earlier, understand why the risk is flagged, and act in time — before deterioration becomes critical. It predicts sepsis up to 48 hours in advance, integrates directly into existing hospital workflows, and uses Explainable AI to ensure clinicians can validate and trust every alert.
But even the best clinical AI only saves lives if it reaches the bedside. That’s the challenge this programme directly addresses. The gap between a technically validated solution and one that’s deployed at scale across NHS trusts isn’t just a regulatory one — it’s commercial, operational, and organisational.
Working with LIHE and the Health Innovation Network puts us closer to the clinical and commissioning ecosystem that shapes how NHS technology decisions get made. That access is invaluable at this stage of our growth.
Part of a Broader Momentum
This selection joins a series of milestones we’ve reached in recent months: ISO 13485:2016 certification, Cyber Essentials Plus accreditation, and our recognition as a Top 15 Medical Start-Up of 2025 at MEDICA.
Each milestone reflects the same underlying conviction: that clinical AI built for frontline realities — predictive, explainable, integrated, and evidence-ready — is what healthcare systems actually need. The Innovate UK accelerator gives us the support to get there faster.
Thank You — and Welcome, Cohort
A huge thank you to Innovate UK, LIHE, and the Health Innovation Network South London for the vote of confidence. And congratulations to the rest of the cohort — we’re excited to build alongside you.
About Aisthesis Medical
Aisthesis Medical is a deep-tech medtech startup developing cutting-edge AI-driven solutions to revolutionize acute care. Founded in 2022, our mission is to save lives by predicting and preventing sepsis before it becomes fatal. Aisthesis Medical is revolutionizing acute care with VIOSync, the first holistic AI-driven sepsis care platform that goes beyond early prediction to guide clinical intervention and optimize patient outcomes. VIOSync, predicts sepsis up to 48 hours earlier, integrates directly into hospital workflows, and optimizes treatment pathways to reduce unnecessary antibiotic use.
Ready to Learn More?
If you’re a hospital system, NHS trust, healthcare investor, or potential clinical partner who’d like to connect — we’d love to hear from you. There’s never been a better moment to have the conversation.
📩 Get in touch: https://aisthesismed.com/contact/
🌐 Learn more about VIOSync: https://aisthesismed.com/product/